Colorectal LLM Wiki

Browse
Home / Procedures / Local Excision of Rectal Neoplasms
Procedure created 2026-08-19 · updated 2026-08-25
colorectalrectal-cancerlocal-excisionTAMISTEM

Local Excision of Rectal Neoplasms

An alternative to radical resection for selected rectal lesions — removes the lesion without a formal oncologic (TME) resection. Content below is from a textbook reference chapter (Sabiston Ch52 - Rectal Cancer Surgery), not primary literature. See Total Mesorectal Excision (TME) & Sphincter-Sparing Resection for the radical alternative.

Endoscopic techniques

Routine polypectomy, endoscopic mucosal resection (EMR), and endoscopic submucosal dissection (ESD) — see Endoscopic Polypectomy, EMR & ESD for the full technique, patient-selection (NICE classification, non-lifting sign), and complication detail (this page's earlier brief mechanistic summary has been superseded by that page). Surgical excision can also be performed via standard transanal excision, transanal MIS (TAMIS), and transanal endoscopic microsurgery (TEM) — the surgical alternatives detailed below.

Endoscopy for transanal removal of large rectal lesions has expanded with improved staging techniques (ERUS, MRI — see Rectal Cancer). Careful digital exam is also accurate at staging lesions within reach of the examining finger — a lesion that is soft to the touch typically is benign. This is particularly true for villous adenomas of the lower rectum, which are commonly amenable to transanal excision or endoscopic excision. Key principle regardless of technique: excision of a lesion with a free margin, to reduce local recurrence risk.

Surgical (transanal) local excision

Traditional criteria for a local excision candidate: small lesions (<2 cm diameter), well-differentiated cancers, and lesions mobile (not fixed) within reach of the index finger. T1 lesions are ideal; patients with T2 or T3 lesions are generally not suitable, as the recurrence rate following local excision in this group has been unacceptable.

T1N0 criteria and outcomes, per ASCRS Ch27 - Rectal Cancer Local Excision: well- to moderately-differentiated tumor, absence of lymphovascular or perineural invasion, and size <3cm occupying less than one-third of the bowel-lumen circumference. Overall LNM risk for T1 rectal tumors is 6–11%, but drops to 6% specifically in the absence of adverse histologic features (Swedish Rectal Cancer Registry analysis). Local excision as sole definitive treatment should be reserved for histologically favorable T1 cancers; T1 tumors with unfavorable histology (LVI, poor differentiation, tumor budding — see Colorectal Polyps) should be considered for proctectomy given LNM risk. A SEER-database analysis found similar cancer-specific survival for local excision vs. radical surgery in T1 rectal cancer; two meta-analyses comparing local excision (TEM subgroup) and proctectomy for T1 rectal cancer found similar 5-year overall survival, though one of the two meta-analyses found inferior oncologic results with local excision overall when all studies (not just the TEM subgroup) were included, and both meta-analyses' evidence base includes only one underpowered RCT, the rest being retrospective cohorts.

Depth of invasion: submucosal invasion is further classified by the Kikuchi (Sm) classification (see Colorectal Polyps for the full Sm1/Sm2/Sm3 definition) — LNM risk is 3% for SM1 (superficial third), rising to 23% for SM3 (deep third); SM3-level invasion behaves similarly to T2 disease oncologically, so local excision should be reserved for superficial or middle-third invasion for the best curative/oncologic results.

Technique: cautery scores a 1-cm margin around the lesion; traction is used, and a full-thickness incision is carried down to perirectal fat. Local excision is safe for lesions located lateral to or posterior to the rectum, given the presence of the mesorectum there. If lesions are located in the anterior rectum: in women, there is risk of iatrogenic rectovaginal fistula (see Rectovaginal Fistula, ASCRS Ch15, which names anterior local excision among its recognized iatrogenic causes); in men, risk of injury to the prostate. Above 6–7 cm, there is also concern that the peritoneal cavity may be entered. These procedures are most safely performed in the lower rectum.

Transanal endoscopic microsurgery (TEM), developed in the early 1990s, made possible the excision of larger lesions, and lesions higher up, than could be safely reached with conventional transanal surgery — but required a specialized rigid-instrument set with a high learning curve. TEM has now largely been supplanted by TAMIS, which uses standard laparoscopic instruments and an access port similar to that used for single-port laparoscopy, inserted in the anal canal. This allows safe excision of lesions above the level of the very distal rectum, but — because the laparoscopic access device itself anchors in place — is not suitable for lesions in the very lower rectum (where standard transanal excision is used instead).

Malignant polyps and early rectal cancer: transanal endoscopic surgery (TES — TEM or TAMIS) is a desirable option over flexible EMR/ESD for benign and malignant polyps located within the rectum specifically, per ASCRS Ch23 - Management of Malignant Polyps — see Colorectal Polyps for the fuller malignant-polyp depth-of-invasion/lymph-node-risk/curative-resection-criteria content this outcome data feeds into. TES removes lesions en bloc in either the submucosal or full-thickness plane, with low rates of specimen fragmentation (<10%) and polyp recurrence (5–11%) reported; the source chapter's cited margin-status figure (66–93%) is reported on Colorectal Polyps exactly as extracted, flagged there as an apparent internal inconsistency (it reads as though it should describe negative rather than positive margins, given its placement in a sentence about "low rates"). A North American multicenter series of rectal ESD (n=171, not TES specifically) found an en-bloc resection rate of 82.5%, R0 resection rate of 74.9%, and cure in 81.8% of malignant polyps with favorable histologic features — offered as a comparison point. TES's downsides: added morbidity from full-thickness resection, long-term functional derangement (especially for distal lesions), and scarring outside the rectal wall that can complicate a subsequent proctectomy if one is later needed.

T2 rectal cancer: a plausible but unproven expansion

Per ASCRS Ch27 - Rectal Cancer Local Excision: proctectomy for T2 rectal cancer achieves high cure rates but at the cost of high morbidity, permanent-colostomy risk, and anorectal/sexual/urinary functional impairment — driving continued interest in organ preservation for T2 disease despite the standard recommendation remaining radical resection given T2's high risk of lymph node metastasis.

  • Local excision alone for T2 carries unacceptably high locoregional recurrence: reported ranges of 13–30% (partly attributable to 30–40% occult nodal involvement) and, in one comparative series, a 5-year local recurrence rate of 47% with local excision alone vs. 6% with proctectomy, and 5-year overall survival of 65% vs. 81% respectively. A SEER-program analysis found more than 20% of T2 patients are nonetheless treated with local excision, with suboptimal overall survival in that group.
  • Local excision + adjuvant or neoadjuvant chemoradiotherapy for T2 disease has shown more promising results (see Adjuvant and neoadjuvant therapy below) and is an area of active clinical investigation for expanding organ-preservation eligibility, though it remains off standard of care.

Complications

Per ASCRS Ch27 - Rectal Cancer Local Excision: complication rates for local excision, regardless of technique (transanal excision, TEM, or TAMIS), are lower than for radical surgery.

  • Urinary retention — the most common complication, up to 5% of patients; usually self-limited from pressure on the urethra, anal stretch, edema, and pain; managed with self-catheterization or a temporary indwelling catheter.
  • Postoperative bleeding — up to 5%, usually within several days postop, often corresponding to suture-line dehiscence, scab sloughing, or anticoagulation. Minor bleeding is often self-limited; frank hemorrhage warrants resuscitation, endoscopic evaluation, and treatment (monopolar cautery, sutures, and/or epinephrine injection). Major intraoperative bleeding is rare.
  • Pelvic abscess — can occur; whether it's more common with an open vs. closed extraperitoneal defect is unresolved and debated. Defects breaching the peritoneum necessitate closure.
  • Other complications: wound infections, thromboembolic events, rectal strictures, and rectovaginal fistulas (uncommon) — see Rectovaginal Fistula (ASCRS Ch15) for that specific risk in anterior lesions, already noted above.
  • Defect closure vs. leaving open: evidence is mixed and management is largely surgeon's discretion. A single RCT (n=44, likely underpowered) found no difference in early or late complications between closure and leaving the wound open. A larger multi-institutional matched analysis (991 patients) similarly found no difference in 30-day postoperative morbidity between closure and open management.

Oncologic results

Per ASCRS Ch27 - Rectal Cancer Local Excision:

  • T1 cancer: local excision is an acceptable oncologic strategy for T1 rectal cancer with favorable histology (well-to-moderately differentiated, no LVI/perineural invasion, <3cm, <1/3 circumference). A positive margin after local excision is associated with higher recurrence risk and lower 5-year overall survival. A prospectively-collected UK 21-center collaborative (424 patients undergoing TEM ± adjuvant/neoadjuvant radiotherapy) found positive margins in 11%, 23%, and 42% of pT1, pT2, and pT3 tumors respectively. Local recurrence after TEM for T1 disease in that same cohort was 10%, 13%, and 19% at years 2, 3, and 5 — associated with depth of invasion, tumor maximum diameter, and lymphovascular invasion: favorable tumors (no LVI, SM1) had 3–8% local recurrence depending on size, vs. 18–42% for unfavorable tumors (LVI-positive, SM2–3). Junginger et al.'s long-term outcomes series (median follow-up 8.6 years) found 5-/10-year local recurrence of 7%/12% for low-risk tumors vs. 32%/35% for high-risk tumors, and 5-/10-year cancer-specific survival of 98%/91% vs. 84.3%/74.3% respectively (p=0.05) — reinforcing that limiting local excision to favorable-histology T1 disease minimizes recurrence risk.
  • T2 cancer: see the T2 section above for local-excision-alone outcomes (unfavorable) vs. combined with adjuvant/neoadjuvant therapy (below).

Adjuvant and neoadjuvant therapy combined with local excision

Per ASCRS Ch27 - Rectal Cancer Local Excision — general neoadjuvant chemoradiotherapy regimen detail (CRT/SCRT dosing, chemotherapy backbone) lives on Total Neoadjuvant Therapy (TNT) and is not repeated here; this section covers evidence specific to combining that therapy with local excision rather than radical resection:

  • Adjuvant therapy after local excision (CALGB 8984): T1 rectal cancer treated with local excision alone vs. T2 rectal cancer treated with local excision followed by adjuvant chemoradiotherapy — despite adjuvant therapy, the T2 group had worse 10-year overall survival and disease-free survival, and a higher rate of local recurrence (18% vs. 8%). A meta-analysis of 14 studies on local excision followed by either adjuvant chemoradiotherapy or completion surgery for T1/T2 rectal cancer found local recurrence of 15% (range 11–21%) with adjuvant chemoradiotherapy vs. 10% (range 4–22%) with completion proctectomy after initial local excision for T2 tumors — a separate systematic review (Cutting et al.) found local recurrence rates of 6% (T1), 14% (T2), and 34% (T3) after local excision + adjuvant therapy. Together these suggest adjuvant therapy after local excision for T2+ disease is inferior to radical surgery but better than local excision alone.
  • Neoadjuvant therapy + local excision (an alternative sequencing, exploring whether occult mesorectal nodal disease can be sterilized preoperatively): up to 30% of patients achieve pathologic complete response with neoadjuvant chemoradiation generally (see Total Neoadjuvant Therapy (TNT)). ACOSOG Z6041 (Garcia-Aguilar et al.), a single-arm phase II trial of 84 T2N0 patients treated with neoadjuvant chemoradiation + local excision, found 64% downstaging.

Flag — patient-count discrepancy across textbook chapters for the same trial: ASCRS Ch30 - Colorectal Cancer Postoperative Adjuvant Therapy and Surveillance cites ACOSOG Z6041 as enrolling 79 patients with cT2N0M0 distal rectal cancer (vs. 84 cited by this chapter/ASCRS Ch27 - Rectal Cancer Local Excision) and reports a 3-year DFS of 87% — "significantly lower than what would be expected for similarly staged patients who underwent proctectomy," concluding this approach should be considered an oncologic compromise for patients unable/unwilling to undergo proctectomy. The DFS figure is a new corroborating data point (not previously on this page); the 79-vs-84 patient count is a minor cross-chapter numeric discrepancy, both textbook-sourced, not adjudicated here per this wiki's practice.

The Lezoche RCT compared local excision vs. laparoscopic proctectomy after neoadjuvant therapy — all patients achieved R0 resection, with similar local recurrence (8% vs. 6%, p=0.609) and cancer-related survival (89% vs. 94%) between arms. GRECCAR 2 (Rullier et al., 2017), a randomized phase III trial of 145 cT2–3 patients treated with neoadjuvant chemoradiation then randomized to local excision or radical surgery, found no statistically significant difference in oncologic outcomes (3-year local recurrence 6% vs. 3%, p=0.63; overall survival 89% vs. 95%, p=0.40) — notably, only 8% of patients who underwent completion radical surgery after local excision had nodal involvement, suggesting radical surgery was unnecessary for most. The CARTS study (T1–3 disease, neoadjuvant chemoradiation + local excision, 35 local-excision vs. 16 radical-resection patients) found a 5-year local recurrence rate of 8%, with 5-year disease-free and overall survival of 82% and 83% respectively. Together these trials suggest local excision after completion of chemoradiation may be an option in selected patients, though wound healing after local excision in a previously-irradiated field is a recognized downside (rectal wall closure breakdown is common), and it remains unclear whether local excision is even necessary in patients who achieve a complete clinical response (see Rectal Cancer's watch-and-wait content). - High-risk histopathologic features prompting proctectomy over adjuvant therapy (per ASCRS Ch30 - Colorectal Cancer Postoperative Adjuvant Therapy and Surveillance's Table 30.2): poor differentiation, lymphovascular invasion, R1 resection, tumor fragmentation during local invasion, and margins positive or <1mm. If any of these features are present after local excision, proctectomy should be considered; if the patient is unwilling or unable to tolerate major abdominal surgery, adjuvant chemoradiation (and possibly chemotherapy) is an alternative. Current NCCN guidelines recommend proctectomy or chemoradiation (capecitabine or infusional 5-FU) for pT2Nx and pT1Nx locally excised tumors with these high-risk features, with proctectomy preferred for pT2Nx tumors in otherwise healthy patients. See Adjuvant Chemotherapy for Colorectal Cancer for the fuller adjuvant-therapy-selection framework this table sits within.

Quality of life

Per ASCRS Ch27 - Rectal Cancer Local Excision: patients with early rectal cancer who undergo local excision report better quality of life and bowel function overall than those undergoing radical resection, despite the functional consequences of rectal-wall resection itself. Pucciarelli et al. found anorectal function 1 year after local excision with neoadjuvant chemoradiation had minimal impact on function and overall quality of life. The CARTS study found health-related quality of life equal to baseline after local excision, with improved emotional well-being compared to radical surgery.

Salvage surgery

Per ASCRS Ch27 - Rectal Cancer Local Excision: use of local excision for early distal rectal cancer has more than doubled over the last two decades, driven by improved surgical platforms, patient preference, and outcome-data publication. Local recurrence is the most common failure pattern after local excision (20–30%). Reported salvage-surgery outcomes are notably inferior to primary radical surgery for early rectal cancer:

  • Bikhchandani et al.: 93% R0 resection rate in 27 patients undergoing multimodal salvage surgery for locally recurrent disease after local excision; 5-year recurrence-free survival 47%, 5-year overall survival 50% — most re-recurrences were distant metastases. Compares unfavorably to the 92–97% 5-year disease-free survival reported for primary radical surgery for early rectal cancer. Other published series similarly found salvage resection for recurrence after local excision associated with only modest oncologic success.
  • You et al.: extended resections for local failure after local excision achieved an R0 rate of only 80%; 3-year re-recurrence-free survival 43%, 5-year overall survival 63%.
  • Friel et al.: outcomes following salvage surgery for recurrence after local excision were inferior to those of initial radical treatment — stressing the importance of appropriate patient selection for local excision and cautioning against assuming salvage surgery will be successful for patients with local failure.

The overall tradeoff local excision makes: increased risk of disease recurrence in exchange for improved function and sphincter preservation. Patients should be counseled explicitly that salvage therapy is not always associated with a good oncologic outcome.

Open items / gaps

  • ~~No primary trial data yet comparing TEM/TAMIS oncologic outcomes to formal TME resection for T1 lesions specifically.~~ Resolved by ASCRS Ch27 - Rectal Cancer Local Excision: a SEER-database analysis and two meta-analyses (one including an underpowered RCT) now provide this comparison — see the T1N0 criteria and Oncologic results sections above. None of these are independently ingested from primary publications, so figures remain textbook-secondary-source-level.
  • No detail on how local excision interacts with the watch-and-wait strategy described on Rectal Cancer (e.g. as a way to remove residual disease after a near-complete response) — this chapter touches on it only briefly (noting it's unclear whether local excision is necessary in complete clinical responders); likely to be addressed more fully by ASCRS Ch28 - Rectal Cancer Nonoperative Management once ingested.
  • Two effect-size discrepancies for LVI's and poor differentiation's association with lymph node metastasis, between this chapter's cited studies and Colorectal Polyps's existing sourcing, are flagged on Colorectal Polyps rather than repeated here.